The guidance withdrawal and strategic alternatives review signal heightened uncertainty around Heron's largest product (CINVANTI) and overall direction. Traders should monitor for updates on the CINVANTI patent appeal, any strategic transaction announcement, and potential equity or debt financing needs. The credit facility amendment provides near-term liquidity relief but does not resolve the core patent risk.
Price Chart
Executive Summary
Heron Therapeutics reported Q2 2026 revenue of $37.7M (missed consensus of $42.2M by 10.7%) and GAAP EPS of -$0.03 (missed -$0.02 by 50%). The company withdrew full-year 2026 guidance and announced a strategic alternatives review, citing uncertainty from a June 2026 court decision on CINVANTI patents. While Acute Care franchise grew 43.9% YoY, Oncology declined 15.9% and the net loss widened to $5.5M.
Key Financial Metrics
Key Facts
- Q2 2026 net revenue $37.7M, up 1.3% YoY but 10.7% below consensus of $42.2M
- GAAP EPS -$0.03 vs consensus -$0.02 (50% miss)
- Full-year 2026 guidance withdrawn due to CINVANTI patent litigation uncertainty
- Strategic alternatives review initiated; no timetable or assurance of transaction
- Acute Care revenue grew 43.9% YoY (ZYNRELEF +35%, APONVIE +74%)
- Oncology revenue declined 15.9% YoY (CINVANTI -9.7%, SUSTOL -77.5%)
- Credit facility amended: $13.5M principal reduction at execution, potential $4M further reduction
- Cash, equivalents and short-term investments $42.7M at quarter end
- Net loss $5.5M vs $2.4M loss in prior year quarter
- Adjusted EBITDA positive at $3.2M vs $2.2M prior year
Financial Impact
Revenue miss of ~$4.5M (10.7%) and EPS miss of $0.01 (50%) relative to consensus; guidance withdrawal creates material uncertainty for valuation
Risk Factors
- CINVANTI generic entry following adverse patent ruling could materially reduce Oncology revenue
- Strategic alternatives review may result in dilutive financing, asset sale, or no transaction
- Continued net losses and negative operating cash flow pressure balance sheet
- Potential Nasdaq minimum bid price compliance risk given current market cap of $93M
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341780 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $0.3350 | awaiting T+60 | — | $0.3000 (+10.45%) |
Aug 10, 2026 11w ago | Press Release | $0.3350 | awaiting T+60 | — | $0.3000 (+10.45%) |
Jun 25, 2026 17w ago | 8-K | $0.4300 $0.2700 | ▲ +37.21% | ▲ +43.31% | $0.3000 (+30.23%) |
Jun 2, 2026 20w ago | 8-K | $0.4500 $0.3321 | ▲ +26.20% | ▲ +28.70% | $0.3000 (+33.33%) |
May 11, 2026 24w ago | 8-K | $0.9600 $0.5048 | ▲ +47.42% | ▲ +51.81% | $0.3000 (+68.75%) |
May 11, 2026 24w ago | Press Release | $0.9600 $0.5048 | ▲ +47.42% | ▲ +51.81% | $0.3000 (+68.75%) |
Apr 30, 2026 25w ago | DEFA14A | $1.20 $0.4592 | ▼ −61.73% | ▼ −64.84% | $0.3000 (−75.00%) |
Apr 27, 2026 26w ago | Press Release | $1.21 $0.4590 | ▼ −62.07% | ▼ −66.06% | $0.3000 (−75.21%) |
Apr 6, 2026 29w ago | 8-K | $0.8100 $0.4244 | ▼ −47.60% | ▼ −61.07% | $0.3000 (−62.96%) |
Feb 26, 2026 34w ago | 8-K | $1.20 $0.8700 | ▼ −27.50% | ▼ −35.25% | $0.3000 (−75.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers